Latest from CANNYX NEWS
Validcare is now working with a second cohort of CBD brands as part of the company’s large scale, human safety study, expanding the reliability of Validcare’s recently completed findings in Cohort 1 regarding liver safety in healthy adults ingesting either full or broad-spectrum hemp-derived CBD.
The Validcare safety study is designed to respond to the FDA’s repeated requests, including the Agency’s March 5, 2020 report to Congress for science-based data, so it can confidently determine the appropriate regulatory path(s) for hemp derived CBD products.
“We welcome the participation of industry-leading Garden of Life, as well as Impact Naturals, Tauriga Sciences, Inc. and others in this important industry led research,” said Keith Aqua, MD, co-principal investigator of this IRB approved study. “The addition of this cohort strengthens the statistical reliability of the liver safety results as well as whether drowsiness or testosterone levels are impacted by long-term CBD consumption. All of these measures are important to FDA and consumers.”
“We’re excited to have our decentralized trial technology overcome the hurdles of performing research during a pandemic”